- Home
- PLUR vs NRSN Comparison
PLUR vs NRSN Comparison
Compare PLUR & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- NRSN
- Stock Information
- Founded
- PLUR 2001
- NRSN 2017
- Country
- PLUR Israel
- NRSN Israel
- Employees
- PLUR N/A
- NRSN N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- NRSN Health Care
- Exchange
- PLUR Nasdaq
- NRSN Nasdaq
- Market Cap
- PLUR 36.9M
- NRSN 29.8M
- IPO Year
- PLUR N/A
- NRSN 2021
- Fundamental
- Price
- PLUR $3.90
- NRSN $1.12
- Analyst Decision
- PLUR Strong Buy
- NRSN Buy
- Analyst Count
- PLUR 1
- NRSN 2
- Target Price
- PLUR $12.00
- NRSN $14.00
- AVG Volume (30 Days)
- PLUR 11.1K
- NRSN 248.2K
- Earning Date
- PLUR 11-11-2025
- NRSN 12-17-2025
- Dividend Yield
- PLUR N/A
- NRSN N/A
- EPS Growth
- PLUR N/A
- NRSN N/A
- EPS
- PLUR N/A
- NRSN N/A
- Revenue
- PLUR $1,336,000.00
- NRSN N/A
- Revenue This Year
- PLUR $97.38
- NRSN N/A
- Revenue Next Year
- PLUR $293.97
- NRSN N/A
- P/E Ratio
- PLUR N/A
- NRSN N/A
- Revenue Growth
- PLUR 309.82
- NRSN N/A
- 52 Week Low
- PLUR $3.33
- NRSN $0.80
- 52 Week High
- PLUR $7.13
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- PLUR 41.43
- NRSN 43.34
- Support Level
- PLUR $3.60
- NRSN $1.15
- Resistance Level
- PLUR $4.00
- NRSN $1.30
- Average True Range (ATR)
- PLUR 0.19
- NRSN 0.08
- MACD
- PLUR -0.01
- NRSN -0.01
- Stochastic Oscillator
- PLUR 29.70
- NRSN 33.96
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.